





Enabling the Next Wave of GWAS with the Axiom<sup>™</sup> Genotyping Solution

Donovan Burger Separation Scientific SA (PTY) LTD

donovan@sepsci.co.za

## **Current Affymetrix Platforms**







### A new ligation-based assay format offers robust & reliable results







## An expanded catalog of human variation will accelerate GWAS



- Discovery initiatives may yield 10X more genetic variants
- A new approach to analyzing and studying genetic diversity
- Incorporating rare alleles (>0.05%) will require significant larger sample size



Introducing Affymetrix' new genotyping system for association studies



## Axiom Genotyping Solution

A universally accepted principle or rule

| Database of<br>validated<br>SNPs               |  |   |                                   |   |  |
|--|--|---|-----------------------------------|---|--|
| AXIOM<br>GENOMIC<br>DATABASE                   | AXIOM<br>CUSTOM &<br>CATALOG<br>ARRAY PLATES                     | BECKMAN<br>BIOMEK FX <sup>P</sup><br>TARGET PREP<br>EXPRESS | Axiom <sup>™</sup><br>Reagent Kit | GENETITAN®<br>System                            | GENOTYPING<br>CONSOLE <sup>TM</sup><br>SOFTWARE  |
| >11M<br>validated<br>common &<br>rare variants | Up to 700k<br>SNP's per<br>array and up<br>to 2.6M per<br>sample | Automated<br>target<br>preparation*                         | New robust<br>& reliable<br>assay | Automated,<br>hands-free<br>array<br>processing | Comprehensive<br>user-friendly<br>software suite |

5

\* Manual target prep protocol also available





# Axiom<sup>™</sup> Genomic Database



Affymetrix has screened all publically available sources of human SNPs using Axiom





Increase your chances of finding associations

- Validated SNPs are:
  - Markers that have been reliably genotyped for the rare allele in the Axiom<sup>™</sup> assay
  - This means that it is shown to be polymorphic in the given population(s) by demonstrating reliable detection of minor allele
- Important to note: Sources of SNP discovery are known to be full of false positives
  - Can have false positive rates as high as 20%
  - Without validating each putative SNP, you don't easily know whether it's mono-morphic (i.e., not a real SNP) or simply did not work well in the assay



# Axiom<sup>™</sup> Genotyping Solution: A comprehensive approach to association studies











\*Screened against HapMap 3 samples featuring 1,301 samples from 11 different populations



Axiom<sup>™</sup> myDesign<sup>™</sup> Genotyping Array Plates are available in different configurations



#### Choose your SNPs from the Axiom Genomic Database or add SNPs from your own database



#### One FTE can support Axiom<sup>™</sup> manual workflow









#### Achieve ~768 samples/week with 8 plate workflow



## Key features of Axiom<sup>™</sup> myDesign<sup>™</sup> Custom Arrays



| Density             |  | 50K – 2.6M  |  |
|---------------------|--|---|--|
| Genome              |  | Human   |  |
| Applications        |  | GWAS, replication, fine mapping, and candidate gene |  |
| Marker type         |  | SNP and simple in/dels                              |  |
| Sources             |  | Axiom Genomic Database<br>De novo, target sequence  |  |
| SNP selection       |  | Manually by customer                                |  |
| SNP list submission |  | Online via myDesign NetAffx<br>Workspace            |  |
| Array design        |  | Affymetrix Bioinformatics                           |  |



#### Axiom<sup>™</sup> myDesign<sup>™</sup> supports several design strategies



#### Leverage content from:

- Axiom Genomic Database
- De novo, target sequence

#### Fully customized

Design an entirely novel Axiom myDesign Array Plate with any density between 50,000 – 2.6 million markers per sample.

- Biological category (cSNPs, MHC, ADME)
- MAF (common, rare SNPs, or both)
- Population (CEU, etc.)
- Genomic region
- Commercially available panels (Affymetrix or ILMN)

#### Semi-customized

Supplement one of the currently available Axiom Genome-Wide Array Plates (CEU or ASI) with additional SNPs (up to 675K):

- Biological category
- MAF
- Population
- Genomic region

\*Axiom YRI available in





Semi-customized design: Supplementing an Axiom<sup>™</sup> Genome-Wide Array



#### Axiom<sup>™</sup> Genome-Wide CEU Array

#### Axiom<sup>™</sup> Genome-Wide ASI Array

- Includes 567K markers
- Supplement with additional 60,000 markers
- Includes 598K markers
- Supplement with additional 40,000 markers



### Axiom<sup>™</sup> myDesign<sup>™</sup> Genotyping Arrays offer three major advantages



| Comprehensive content  | Flexible<br>format  | High<br>quality   |
|--|---|---|
| <ul> <li>Validated 1000 Genomes content</li> <li>Gene function</li> <li>Biological pathway</li> <li>Linkage disequilibrium</li> <li>Minor allele frequency</li> <li>Ethnic population</li> </ul> | <ul> <li>Density: 50K - 2.6M<br/>SNPs array</li> <li>Scalable throughput</li> <li>Manual or automated<br/>workflow</li> <li>Supports GWAS,<br/>replication, and<br/>candidate gene<br/>studies</li> </ul> | <ul> <li>Rigorous functional<br/>testing against<br/>HapMap</li> <li>High pass rate</li> <li>High call rate</li> <li>Highly reproducible</li> </ul> |



## Experimental workflow in human genomics







#### **Axiom™ myDesign ™ Arrays with the Axiom Genomic Database**

- Variety of relevant markers to help scientific discoveries
  - Optimize coverage for your population/cohort
  - Proven to work reliably; no need for optimization
  - Only pay for what you need
- Convenient and easy-to-design arrays with assistance from Bioinformatics Services
- Potential to leverage data sets from previous studies
- Superior data quality with exceptional sample pass rate, call rate, concordance, and reproducibility



Conclusions on combining NGS with microarrays for validation & epidemiology



The combination of NGS (a powerful discovery tool for novel SNPs) and Axiom<sup>™</sup> microarrays offers several distinct advantages over NGS alone.

| Approach                          | Advantage   | Disadvantage  | Mitigation   |  |
|-----------------------------------|---|---|--|--|
| Low-read-<br>depth<br>sequencing  | Fast.<br>Can sequence<br>enough<br>individuals to<br>power<br>epidemiology<br>studies | High rate of false<br>positives & error rate<br>too high for<br>epidemiology studies                      | Axiom <sup>™</sup> myDesign <sup>™</sup><br>Genotyping allows<br>you to:<br>Validate discovery<br>Generate LD & MAF info     |  |
| High-read-<br>depth<br>sequencing | Lower false-<br>positive error<br>rate  | Cannot cost-effectively<br>and quickly sequence<br>enough individuals to<br>power epidemiology<br>studies | <ul> <li>on novel discovery</li> <li>Power your<br/>epidemiology studies<br/>faster and more cost<br/>effectively</li> </ul> |  |







- 1. Affymetrix is a microarray-based solution to analysing GWAS pylomorphism
- 2. It is seen as a COMPLIMENTARY technology to NGS
- 3. Photo lithography allows for extremely high reproducibility of the array and precise concentration and sequences of probes
- 4. Ligation process allows for more stringent washes high specificity
- 5. Affymetrix offers various solution platforms
  - GCS3000 single sample analysis, both expression & genotyping
  - 2. GeneATLAS 4-sample analysis, expression analysis
  - GeneTITAN 96-sample and more analysis, both expression & genotyping
- 6. AXIOM offers both Catalogue as well as customised arrays ranging from 50k to 2.6M data points











# THANK YOU

